Scancell Holdings plc (LON:SCLP – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as GBX 79.80 and last traded at GBX 81, with a volume of 751,889 shares trading hands. The stock had previously closed at GBX 81.
Scancell Stock Performance
The firm’s 50 day moving average is GBX 93.66 and its 200 day moving average is GBX 131.76. The company has a debt-to-equity ratio of -88.01, a quick ratio of 13.01 and a current ratio of 0.28. The stock has a market cap of £1.09 billion, a P/E ratio of -145.64 and a beta of 0.69.
Scancell (LON:SCLP – Get Free Report) last issued its quarterly earnings results on Friday, October 9th. The company reported GBX (17.30) earnings per share (EPS) for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 128.87%. Analysts anticipate that Scancell Holdings plc will post -2.54 EPS for the current year.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Articles
- Five stocks we like better than Scancell
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
